Literature DB >> 2736709

Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

S S Cao1, Y S Zhen.   

Abstract

Previous studies have shown that dipyridamole (DP), a potent nucleoside transport inhibitor blocking the rescue effect of exogenous nucleosides, markedly potentiates the cytotoxicity of antimetabolites. However, no enhancement of the chemotherapeutic effect of antimetabolites by DP in vivo has yet been reported. This study provided evidence that the combination of DP and amphotericin B (AmB) significantly potentiated the inhibitory effect of 5-fluorouracil (FU) or methotrexate (MTX) against a panel of transplantable tumors including sarcoma 180, cervical carcinoma U14, and Lewis lung carcinoma in mice. No significant increase in toxicity was induced by this combination in treated mice. Our results indicate that the combination of DP and AmB with antimetabolites is potentially useful in cancer chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2736709     DOI： 10.1007/bf00300240

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  27 in total

1.  Response of the Gastrointestinal Tract of the Mouse to 5-Fluorouracil.

Authors:  A L Muggia; E Wagman; S S Milles; H M Spiro
Journal:  Am J Pathol       Date:  1963-04       Impact factor: 4.307

2.  Clinical, biological, and biochemical effect of pyrazofurin.

Authors:  E C Cadman; D E Dix; R E Handschumacher
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

Review 3.  Chemotherapeutic inhibitors of the enzymes of the de novo pyrimidine pathway.

Authors:  T W Kensler; D A Cooney
Journal:  Adv Pharmacol Chemother       Date:  1981

Review 4.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

Authors:  G Weber
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

5.  [A comparison of the destructive effects of five antitumour agents on various normal tissues in mice].

Authors:  Y S Cheng; H T Li; J Yang
Journal:  Yao Xue Xue Bao       Date:  1965-09

6.  Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.

Authors:  C A Presant; S Hillinger; C Klahr
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

7.  Salvage pathways as targets of chemotherapy.

Authors:  G Weber; H N Jayaram; K Pillwein; Y Natsumeda; M A Reardon; Y S Zhen
Journal:  Adv Enzyme Regul       Date:  1987

Review 8.  Advances in rational combination chemotherapy.

Authors:  L E Damon; E C Cadman
Journal:  Cancer Invest       Date:  1986       Impact factor: 2.176

9.  Amphotericin B renders stationary phase hepatoma cells sensitive to dipyridamole.

Authors:  Y S Zhen; M A Reardon; G Weber
Journal:  Biochem Biophys Res Commun       Date:  1986-10-15       Impact factor: 3.575

10.  Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line.

Authors:  A F Sobrero; J R Bertino
Journal:  Cancer Treat Rep       Date:  1985-03
View more
  30 in total

1.  Antiproliferation and apoptosis induction of paeonol in HepG2 cells.

Authors:  Shu-Ping Xu; Guo-Ping Sun; Yu-Xian Shen; Wei Wei; Wan-Ren Peng; Hua Wang
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

2.  Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation.

Authors:  Chuan-Kun Shan; Yi-Bo Du; Xiao-Tian Zhai; Yue-Xuan Wang; Yi Li; Jian-Hua Gong; Zhi-Juan Ge; Xiu-Jun Liu; Yong-Su Zhen
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

3.  Co-inhibition of ATM and ROCK synergistically improves cell proliferation in replicative senescence by activating FOXM1 and E2F1.

Authors:  Eun Jae Yang; Ji Hwan Park; Hyun-Ji Cho; Jeong-A Hwang; Seung-Hwa Woo; Chi Hyun Park; Sung Young Kim; Joon Tae Park; Sang Chul Park; Daehee Hwang; Young-Sam Lee
Journal:  Commun Biol       Date:  2022-07-14

4.  NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells.

Authors:  Shan Li; Feng Wang; Gang Zhang; Tsui-Fen Chou
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

5.  Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.

Authors:  J Su; Y C Zhen; C Q Qi; J L Hu
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model.

Authors:  Zi-Yu Jiang; Shu-Kui Qin; Xiao-Jin Yin; Ya-Li Chen; Lin Zhu
Journal:  Exp Ther Med       Date:  2012-05-18       Impact factor: 2.447

7.  Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.

Authors:  Melchiorre Cervello; Dimcho Bachvarov; Nadia Lampiasi; Antonella Cusimano; Antonina Azzolina; James A McCubrey; Giuseppe Montalto
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

8.  TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro.

Authors:  Bo Qiu; Xiyang Sun; Dongyong Zhang; Yong Wang; Jun Tao; Shaowu Ou
Journal:  Int J Mol Sci       Date:  2012-07-20       Impact factor: 6.208

9.  An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.

Authors:  Miho Ushijima; Masaki Shiota; Takashi Matsumoto; Eiji Kashiwagi; Junichi Inokuchi; Masatoshi Eto
Journal:  Cancer Sci       Date:  2022-04-01       Impact factor: 6.518

10.  Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells.

Authors:  M Assem; S Bonvalot; J L Beltramo; C Garrido; M T Dimanche-Boitrel; P Genne; J M Rebibou; D Caillot; B Chauffert
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.